SAN DIEGO, Dec. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants who have dyskinetic cerebral palsy (DCP) did not...
Hence then, the article about neurocrine biosciences provides update on phase 3 study of valbenazine in dyskinetic cerebral palsy was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy )
Also on site :
- For Iran’s Rulers, Refusing U.S. Demands Is a Risk Worth Taking
- Masonite International Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - DOOR
- Battered by Gaza war, Israel's tech sector in recovery mode